What works well for me, and should for any biotech investor, is well designed trials with readouts that are complete, positive and irrefutable per protocol and if changed done in a clear manner supported by relevant regulators and made public well before readout instead of post hoc.
Some seem to believe that it is too much to ask of a pet biotech company with a revered TGD.
News 
Market Data 
Discover 
AI
